Cutaneous melanoma · line 1 · Nivolumab + ipilimumab (melanoma, 1L metastatic)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	standard
Linked regimen	`REG-NIVO-IPI-MELANOMA`

ID	`IND-MELANOMA-METASTATIC-1L-NIVO-IPI`
Type	Indication
Status	status not declared
Diseases	`DIS-MELANOMA`
Sources	`SRC-CHECKMATE-067-LARKIN-2019` `SRC-ESMO-MELANOMA-2024` `SRC-NCCN-MELANOMA-2025`

Notes

CheckMate-067 7.5y OS 49%. Brain-met-active.

Used By

Algorithms

ALGO-MELANOMA-METASTATIC-1L - ALGO-MELANOMA-METASTATIC-1L

Handbook Chapters

HB-MELANOMA-METASTATIC-1L - Metastatic melanoma: BRAF / IO first-line reasoning

Handbook Questions

HQ-MELANOMA-MET-1L-001 - HQ-MELANOMA-MET-1L-001